- Home
- BNY vs OBIO Comparison
BNY vs OBIO Comparison
Compare BNY & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- OBIO
- Stock Information
- Founded
- BNY 2001
- OBIO 2017
- Country
- BNY United States
- OBIO United States
- Employees
- BNY N/A
- OBIO N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- BNY Finance
- OBIO Health Care
- Exchange
- BNY Nasdaq
- OBIO Nasdaq
- Market Cap
- BNY 246.8M
- OBIO 151.3M
- IPO Year
- BNY N/A
- OBIO N/A
- Fundamental
- Price
- BNY $10.28
- OBIO $3.84
- Analyst Decision
- BNY
- OBIO Strong Buy
- Analyst Count
- BNY 0
- OBIO 4
- Target Price
- BNY N/A
- OBIO $16.25
- AVG Volume (30 Days)
- BNY 52.7K
- OBIO 51.4K
- Earning Date
- BNY 01-01-0001
- OBIO 03-26-2025
- Dividend Yield
- BNY 3.93%
- OBIO N/A
- EPS Growth
- BNY N/A
- OBIO N/A
- EPS
- BNY N/A
- OBIO N/A
- Revenue
- BNY N/A
- OBIO $2,647,000.00
- Revenue This Year
- BNY N/A
- OBIO $22.61
- Revenue Next Year
- BNY N/A
- OBIO $16.64
- P/E Ratio
- BNY N/A
- OBIO N/A
- Revenue Growth
- BNY N/A
- OBIO N/A
- 52 Week Low
- BNY $8.60
- OBIO $3.75
- 52 Week High
- BNY $10.80
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- BNY 32.26
- OBIO 33.88
- Support Level
- BNY $10.40
- OBIO $3.78
- Resistance Level
- BNY $10.67
- OBIO $4.18
- Average True Range (ATR)
- BNY 0.09
- OBIO 0.41
- MACD
- BNY -0.03
- OBIO -0.07
- Stochastic Oscillator
- BNY 17.02
- OBIO 6.52
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.